RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis

• Published in: Respiratory medicine Vol. 122; pp. S14 - S17
• Main Authors: Distler, Oliver, Pope, Janet, Denton, Chris, Allanore, Yannick, Matucci-Cerinic, Marco, de Oliveira Pena, Janethe, Khanna, Dinesh
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2017
• Subjects: Carbon Monoxide - metabolism; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Activators - therapeutic use; Female; Fibrosis; Humans; Hypertension, Pulmonary - drug therapy; Male; Pulmonary Diffusing Capacity - drug effects; Pulmonary Embolism - drug therapy; Pulmonary/Respiratory; Pyrazoles - administration & dosage; Pyrazoles - pharmacology; Pyrimidines - administration & dosage; Pyrimidines - pharmacology; Quality of Life; Riociguat; Scleroderma, Diffuse - drug therapy; Scleroderma, Systemic - classification; Skin - drug effects; Skin - pathology; Skin Diseases - drug therapy; Soluble guanylate cyclase; Soluble Guanylyl Cyclase; Systemic sclerosis; Treatment Outcome; Vital Capacity - drug effects; Riociguat; Systemic sclerosis; Soluble guanylate cyclase; Fibrosis

RISE-SSc is a randomized, double-blind, placebo-controlled phase 2 study investigating the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc). Based on positive results from riociguat trials in patients with pulmonary hypertension and chronic thromboemboli...